Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bausch + Lomb Corporation (BLCO : NYSE)

• Company Description    Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R). Bausch Lomb Corporation is based in VAUGHAN, ON. Number of Employees: 13,500

• Price / Volume Information    Yesterday's Closing Price: $18.30 Daily Weekly Monthly 20 Day Moving Average: 441,208 shares Shares Outstanding: 354.29 (millions) Market Capitalization: $6,483.58 (millions) Beta: 0.58 52 Week High: $18.92 52 Week Low: $10.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 9.58% 10.54% 12 Week 8.80% 8.66% Year To Date 7.14% 6.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 520 APPLEWOOD CRESCENT - VAUGHAN,A6 L4K 4B4 CAN ph: 905-695-7700 fax: - None http://www.bausch.com

• General Corporate Information    Officers Brenton L. Saunders - Chairman of the Board and Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Offic Frederick J. Munsch - Senior Vice President; Controller and Chief Accoun Brett Icahn - Director Gary Hu - Director Peer Information Bausch + Lomb Corporation (CHCR) Bausch + Lomb Corporation (ESRX) Bausch + Lomb Corporation (MYDP) Bausch + Lomb Corporation (COR) Bausch + Lomb Corporation (GBCS) Bausch + Lomb Corporation (LAXAF) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Medical Services Sector: Medical CUSIP: 071705107 SIC: 3851 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 04/29/26 Share - Related Items Shares Outstanding: 354.29 Most Recent Split Date: (:1) Beta: 0.58 Market Capitalization: $6,483.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.07 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.79 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 30.72% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/29/26

• Fundamental Ratios P/E Current FY Estimate: 23.10 Trailing 12 Months: 36.60 PEG Ratio: 0.75 Price Ratios Price/Book: 0.99 Price/Cash Flow: 10.97 Price / Sales: 1.27 EPS Growth vs. Year Ago Period: 28.00% vs. Previous Quarter: 77.78% Sales Growth vs. Year Ago Period: 9.77% vs. Previous Quarter: 9.68% ROE 12/31/25 - 2.77 09/30/25 - 2.42 06/30/25 - 2.33 ROA 12/31/25 - 1.31 09/30/25 - 1.15 06/30/25 - 1.12 Current Ratio 12/31/25 - 1.55 09/30/25 - 1.51 06/30/25 - 1.55 Quick Ratio 12/31/25 - 1.04 09/30/25 - 0.98 06/30/25 - 0.98 Operating Margin 12/31/25 - 3.53 09/30/25 - 3.16 06/30/25 - 3.11 Net Margin 12/31/25 - -7.06 09/30/25 - -6.13 06/30/25 - -5.58 Pre-Tax Margin 12/31/25 - -6.21 09/30/25 - -6.83 06/30/25 - -8.08 Book Value 12/31/25 - 18.40 09/30/25 - 18.36 06/30/25 - 18.39 Inventory Turnover 12/31/25 - 2.02 09/30/25 - 1.96 06/30/25 - 1.86 Debt-to-Equity 12/31/25 - 0.77 09/30/25 - 0.76 06/30/25 - 0.76 Debt-to-Capital 12/31/25 - 43.62 09/30/25 - 43.09 06/30/25 - 43.11

Powered by Zacks Investment Research ©